Stock AXSM AXSOME THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
71.17 USD -2.61% Intraday chart for Axsome Therapeutics, Inc. +2.09% -10.58%
Apr. 02 Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing MT
Apr. 01 Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder CI

Business Summary

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Number of employees: 545

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Therapies
100.0 %
50 100.0 % 271 100.0 % +440.80%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
72.9 %
50 100.0 % 197 72.9 % +294.16%
Non-United States
27.1 %
-- 73 27.1 % -

Managers

Managers TitleAgeSince
Herriott Tabuteau CEO
 Chief Executive Officer 55 12-01-11
Nick Pizzie DFI
 Director of Finance/CFO 49 18-05-15
Mark Jacobson COO
 Chief Operating Officer 40 14-03-31
Hunter Murdock LAW
 General Counsel 44 21-11-30
Lori Englebert PRN
 Corporate Officer/Principal 46 20-07-31

Members of the board

Members of the board TitleAgeSince
Mark Saad BRD
 Director/Board Member 54 14-11-30
Susan Mahony BRD
 Director/Board Member 60 23-10-10
Roger Jeffs BRD
 Director/Board Member 62 14-11-30
Herriott Tabuteau CEO
 Chief Executive Officer 55 12-01-11
Mark Herbert Coleman BRD
 Director/Board Member 56 14-11-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 47,374,375 38,224,706 ( 80.69 %) 0 80.69 %

Shareholders

NameEquities%Valuation
Herriott Tabuteau
15.52 %
7,351,729 15.52 % 587 M $
RTW Investments LP
9.477 %
4,489,596 9.477 % 358 M $
Vanguard Fiduciary Trust Co.
7.803 %
3,696,766 7.803 % 295 M $
BlackRock Advisors LLC
6.275 %
2,972,827 6.275 % 237 M $
Fairmount Funds Management LLC
4.982 %
2,360,077 4.982 % 188 M $
BVF, Inc.
4.182 %
1,981,100 4.182 % 158 M $
Citadel Securities GP LLC
2.299 %
1,089,085 2.299 % 87 M $
Perceptive Advisors LLC
2.191 %
1,038,019 2.191 % 83 M $
Deep Track Capital LP
2.111 %
1,000,000 2.111 % 80 M $
RA Capital Management LP
2.111 %
1,000,000 2.111 % 80 M $

Company contact information

Axsome Therapeutics, Inc.

One World Trade Center 22nd floor

10007, New York

+212 332 3241

http://www.axsome.com
address Axsome Therapeutics, Inc.(AXSM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for Axsome Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
71.17 USD
Average target price
121.1 USD
Spread / Average Target
+70.19%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
AXSOME THERAPEUTICS, INC. Stock Axsome Therapeutics, Inc.
-10.58% 3.37B
CSL LIMITED Stock CSL Limited
-2.86% 87.31B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.95% 40.86B
BIOGEN INC. Stock Biogen Inc.
-21.94% 29.36B
UCB Stock UCB
+55.70% 24.49B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-5.41% 17.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.23% 11.26B
INCYTE CORPORATION Stock Incyte Corporation
-17.60% 11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-13.96% 11.31B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+7.87% 8.31B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. AXSM Stock
  4. Company Axsome Therapeutics, Inc.